Curanex Pharmaceuticals Completes Initial Public Offering for $15 Million

Curanex Pharmaceuticals Inc. completed its initial public offering, raising $15 million through the sale of 3.75 million shares at $4 each. The company's shares began trading on the Nasdaq Capital Market under the ticker symbol "CURX." Dominari Securities LLC acted as the lead underwriter, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters. The offering was conducted on a firm commitment basis, with an option to purchase up to 562,500 additional shares within 45 days.

Curanex Pharmaceuticals Inc. (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has successfully completed its Initial Public Offering (IPO). The company raised $15 million in gross proceeds through the offering of 3,750,000 shares at $4.00 per share [1].

Trading of CURX shares commenced on the Nasdaq Capital Market on August 26, 2025. The underwriters, led by Dominari Securities LLC, have a 45-day option to purchase up to 562,500 additional shares at the public offering price, less underwriting discounts and expenses [1].

This capital raise represents a critical funding milestone for Curanex as a developmental stage pharmaceutical company. The $15 million gross proceeds should provide runway for advancing its research pipeline, though this represents a relatively modest IPO by biotech standards [1].

The offering size and $4.00 share price position Curanex in the micro-cap segment of the biotech market. Investors should note that developmental-stage pharmaceutical companies typically face a long pathway to potential commercialization, with significant R&D costs and regulatory hurdles before generating product revenue [1].

References:
[1] https://www.stocktitan.net/news/CURX/curanex-pharmaceuticals-inc-announces-closing-of-its-initial-public-pu072jo6qwxe.html